Tag Archive for: oncology

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – SimBioSys, a leading innovator in precision oncology, and General […]

STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024

Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024 26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, […]

Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other income above plan Conference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT Ladenburg, Germany, 25 […]

4SC AG provides results for financial year 2023 and outlook for 2024

Planegg-Martinsried, Germany, 22 March 2024 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 2023, presenting all material reporting period developments and providing an outlook for 2024. The full report is available at 4SC’s website. Jason Loveridge, Ph.D., CEO of 4SC, commented: “2023 was a real breakout year for […]

Poolbeg Pharma plc – Notice of Allowance for Significant POLB 001 Patent in United States

Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio 20 March 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received a Notice of Allowance from the US Patent Office in […]